BioAgilytix

BioAgilytix is onsite at the 17th EBF Open Symposium and ready to connect! We are feeling inspired as we discuss the latest scientific advancements and explore ways to push the boundaries of bioanalytical research. Stop by booth 3C to learn more about how BioAgilytix is driving innovation in bioanalysis, from large molecule bioanalytics to cell-based assays and biomarkers. Let’s explore how we can collaborate to support the success of your drug development projects. https://lnkd.in/dBDXAC2t #EBF2024 #lifesciences #Immunogenicity #Biomarkers #healthcare #futuremedicine #innovationinscience?

In our upcoming webinar hosted by the American Association of Pharmaceutical Scientists (AAPS) | @aapscomms, we will explore a series of case studies highlighting the critical bioanalytical testing and CMC characterization approaches necessary to support ADC development. Chief Scientific Officer, Jim McNally, PhD will moderate the discussion covering topics, including bioanalytical methods for PK and immunogenicity, as well as CMC characterization techniques. AAPS webinars are open to members and non-members. A free AAPS online account is required to register for the webinar. https://bit.ly/4eH9F8b #AntibodyDrugConjugates #ADCs #Pharmacokinetics #Immunogenicity #AAPS #Bioanalytical #CMCCharacterization #bioanalysis #LCMS #MassSpectrometry #PotencyAssays #Pharma #DrugDevelopment

Our team is now onsite at #ACTOX2024 and ready to engage. Come talk to our experts at booth 203 and learn how BioAgilytix ensures rigorous compliance with regulatory standards for bioanalytical studies during GLP toxicity testing, utilizing validated methodologies to support the safe development of innovative therapies. #BioAgilytix #ACT2024 #Toxicology #DrugDevelopment #AustinTexas #pharmacokinetics #immunogenicity #biomarkers

We are just a few days away from the 17th EBF Open Symposium, happening from 20 – 22 November in Barcelona, Spain. Whether you're looking to explore the latest bioanalytical techniques or connect with fellow professionals, this event offers a valuable opportunity to enhance your knowledge and expand your network. While you're there, be sure to check out our three presentations and two poster sessions led by our talented scientific team from Hamburg. Additionally, our experts will be onsite at booth 3C to discuss the services we offer, ranging from bioanalytical solutions to regulatory support. Stop by to learn more about how we can support your bioanalytical needs and help drive your projects forward. Schedule a meeting with us at EBF! https://bit.ly/3AydM8l #EBF2024 #PrecisionMedicine #lifesciences #healthcare #futuremedicine #InnovationInScience

In today’s rapidly evolving biotech landscape, what qualities do you think are most essential for leaders to drive innovation and support team growth? At BioAgilytix, we value qualities such as innovation, a client-centric focus, and people development. To support our strategic growth, we’re welcoming two industry powerhouses who exemplify these qualities: Mehul Patel as Chief Information Officer (CIO) and Rebecca N. as Chief People Officer (CPO)! With decades of experience and a shared commitment to excellence, Mehul and Rebecca are set to elevate our capabilities, foster an innovative culture, and deliver impactful solutions that empower client success. Their expertise will be instrumental as BioAgilytix continues its expansion across North America, Europe, and Australia. These invaluable hires underscore our commitment to growth and reinforce our position as a trusted leader in bioanalytical services. Join us in welcoming our new leaders as we continue to strive toward excellence and our next phase of growth ???? https://lnkd.in/ePUDCcsv #BioAgilytix #Leadership #Innovation #Biotech #LifeSciences #GlobalExpansion #ClientSuccess

BioAgilytix is excited to attend the upcoming PBSS International Conference in the San Francisco Bay Area on November 15. This bioanalytical workshop will address the challenges of applying traditional techniques, like LBAs and LC-MS, to new therapeutic modalities, focusing on pharmacokinetics, immunogenicity, and regulatory hurdles, with case studies offering practical solutions. Come connect with Amanda Hays, PhD and Yoshio Boris to discuss BioAgilytix's expertise in immunogenicity and pharmacokinetic (PK) assessments, and how our advanced bioanalytical services support the development of biologics and cell/gene therapies. #BioAgilytix #Innovation #Pharma #LifeSciences #CRO #PBSS

Take the opportunity to meet our CEO, Davide Molho DVM, during the 17th EBF Open Symposium next week in Barcelona. He will be onsite with the BioAgilytix team and is looking forward to discussing our bioanalytical solutions to support your next project. Be sure to stop by booth 3C to say hello or book a meeting in advance! https://lnkd.in/da7AzMAU

Our CEO, Davide Molho DVM, and a fantastic group of BioAgilytix employees had the privilege of attending the Triangle Business Journal’s Fast 50 Awards ceremony at Angus Barn! We were honored to be recognized for our employees’ contributions as a leader of scientific excellence, quality, and customer service within the biologic and pharmaceutical industries. A huge thank you to our employees and customers who contributed to our success and to Triangle Business Journal for hosting such a wonderful event – and congratulations to the other outstanding recipient companies! Here’s to continued growth and collaboration as we drive forward in the bioanalytical industry! Did you know that BioAgilytix supported more than 30% of the biologics approved by the FDA between 2018 and 2023? If you want to read more on how we are shaping the future of bioanalytics, dive into our latest press release to learn about our Fast 50 recognition and the inspiring work driving our growth! https://bit.ly/4etzmJc #Fast50 #TBJFast50 #TeamBioAgilytix #Celebration #Networking #Innovation #Growth

Will you be attending the American College of Toxicology (ACT) meeting in Austin, Texas on November 17-20? Don't miss Michelle Miller, PhD's presentation “Strategies for Long-Term Success: Streamlining the Preclinical to Clinical Assay Transition” happening on November 19 at 8:00 AM. Schedule a meeting with our team at booth 203 to discuss our capabilities in toxicology study analysis, including key areas like pharmacokinetics, immunogenicity, and biomarker analysis. BioAgilytix offers tailored GLP and non-GLP bioanalytical strategies using a fit-for-purpose approach designed to meet the unique requirements of each drug program and assay type, ensuring fast, accurate data that align with industry standards and regulatory expectations for IND-enabling programs. We’d love to explore how our flexible, partner-focused approach can support your specific research needs! Learn more: https://bit.ly/3YzicUC #BioAgilytix #ACT2024 #Toxicology #DrugDevelopment #AustinTexas #ACTOX2024 #pharmacokinetics #immunogenicity #biomarkers

Join us at #ACTOX2024 for our breakfast presentation, “Strategies for Long-Term Success: Streamlining the Preclinical to Clinical Assay Transition,” led by scientific officer Michelle Miller, PhD in room 202. Attendees will gain valuable insights into optimizing bioanalytical workflows, from preclinical assay design and critical reagent management to phase-appropriate regulatory compliance. Be sure to get there early for the complimentary breakfast buffet, beginning at 7:45 AM. Engage with our experts at booth 203 and learn how BioAgilytix’s approach drives efficient, cost-effective drug development through seamless assay transitions. Schedule a meeting in advance or stop by booth 203 to connect with our team about your bioanalytical needs. #BioAgilytix #ACT2024 #Toxicology #DrugDevelopment #AustinTexas #ACTOX2024 #pharmacokinetics #immunogenicity #biomarkers https://bit.ly/3YzicUC